Detection and identification of cytochrome P-4502C9 alleles*1,*2, and*3 by high-resolution melting curve analysis of PCR amplicons

被引:18
作者
Hill, CE [1 ]
Duncan, A [1 ]
Wirth, D [1 ]
Nolte, FS [1 ]
机构
[1] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
关键词
melting analysis; polymerase chain reaction; PCR; P-450; genotyping; warfarin; anticoagulation; pharmacogenomics;
D O I
10.1309/76QPHQ892F17QKNC
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
High-resolution melting curve analysis using a fluorescent DNA binding dye can detect sequence variations in a closed-tube system without labeled primers or probes. We developed and verified a melting analysis assay for common single nucleotide polymorphisms of cytochrome P-450 (CYP) 2C9 that affect warfarin metabolism. We used this method to genotype 84 patients receiving warfarin. For wild-type, *1/*1, 50% fluorescence corresponded to a mean +/- SD of 87.17 +/- 0.05 degrees C, whereas *2/*2 was 0.4 degrees C lower The *1/*2 melting curve was easily distinguished from *1/*1 and *2/*2 based on transition temperature and shape. Exon 7 showed a more complex melting curve; however, genotypes *1/*1, *1/*3, and *3/*3 were easily distinguishable. Melting curves were highly reproducible (SD of temperature for multiple fluorescence values 0.04 degrees C-0.11 degrees C; mean, 0.06 degrees C). Heterozygotes (*1/*2 or *1/*3) required significantly lower mean maintenance warfarin doses compared with wild-type (30.67 and 29.56 vs 42.81 mg/wk; P < .05). High-resolution melting analysis provides a simple and accurate method for genotyping of CYP2C9.
引用
收藏
页码:584 / 591
页数:8
相关论文
共 17 条
[1]   Amplicon melting analysis with labeled primers: A closed-tube method for differentiating homozygotes and heterozygotes [J].
Gundry, CN ;
Vandersteen, JG ;
Reed, GH ;
Pryor, RJ ;
Chen, J ;
Wittwer, CT .
CLINICAL CHEMISTRY, 2003, 49 (03) :396-406
[2]   Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J].
Higashi, MK ;
Veenstra, DL ;
Kondo, LML ;
Wittkowsky, AK ;
Srinouanprachanh, SL ;
Farin, FM ;
Rettie, AE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1690-1698
[3]  
*HUM CYT P450 ALL, INCL CRIT
[4]   Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin [J].
Kidd, RS ;
Curry, TB ;
Gallagher, S ;
Edeki, T ;
Blaisdell, J ;
Goldstein, JA .
PHARMACOGENETICS, 2001, 11 (09) :803-808
[5]  
Lay MJ, 1997, CLIN CHEM, V43, P2262
[6]   Cytochrome P4502C9 polymorphisms: a comprehensive review of the in-vitro and human data [J].
Lee, CR ;
Goldstein, JA ;
Pieper, JA .
PHARMACOGENETICS, 2002, 12 (03) :251-263
[7]   Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons [J].
Liew, M ;
Pryor, R ;
Palais, R ;
Meadows, C ;
Erali, M ;
Lyon, E ;
Wittwer, C .
CLINICAL CHEMISTRY, 2004, 50 (07) :1156-1164
[8]   Warfarin dose adjustments based on CYP2C9 genetic polymorphisms [J].
Linder, MW ;
Looney, S ;
Adams, JE ;
Johnson, N ;
Antonino-Green, D ;
Lacefield, N ;
Bukaveckas, BL ;
Valdes, R .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2002, 14 (03) :227-232
[9]   The management of coumarin-induced over-anticoagulation [J].
Makris, M ;
Watson, HG .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (02) :271-280
[10]   Genetic analysis of CYP2C9 polymorphism in a Japanese population [J].
Nasu, K ;
Kubota, T ;
Ishizaki, T .
PHARMACOGENETICS, 1997, 7 (05) :405-409